公开(公告)号：EP4372003A8

公开(公告)日：2024-10-02

申请号：EP22841217.7

申请日：2022-07-04

Applicant: Senboll Biotechnology Co., Ltd.

Inventor： GUO, Jian ,  WANG, Xinying ,  ZHOU, Yaxian ,  WAN, Desen ,  FANG, Yujing ,  OU, Qingjian ,  FAN, Tingting

IPC: C07K16/18 ,  G01N33/68 ,  G01N33/577 ,  G01N33/574

CPC classification number: G01N33/57419 ,  G01N33/57446 ,  G01N33/6893 ,  G01N2800/06720130101 ,  G01N2800/06220130101 ,  G01N2800/06520130101 ,  C07K16/18 ,  C07K16/26 ,  C07K2317/9220130101

Abstract: The present invention provides an antibody combination that can be used to detect regenerating islet-derived protein 1α (REGIA), each antibody in the antibody combination can specifically bind to REG1A with high affinity so as to form a double-antibody sandwich form, thereby enabling qualitative and quantitative detection of human REG1A. The antibody combination or an ELISA detection kit comprising the antibody combination can be used for auxiliary diagnosis or disease risk prediction of REG1A-related diseases.

公开(公告)号：EP3380523A1

公开(公告)日：2018-10-03

申请号：EP16816789.8

申请日：2016-11-22

Applicant: Five Prime Therapeutics, Inc.

Inventor： PIERCE, Kristen ,  POWERS, Janine ,  PALENCIA, Servando ,  SIKORSKI, Robert ,  GHODDUSI, Majid ,  KRISHNAN, Kartik

IPC: C07K16/28 ,  G01N33/574

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55 ,  C07K16/2818 ,  C07K16/2896 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3069 ,  C07K16/3084 ,  C07K2317/34 ,  C07K2317/41 ,  G01N33/5091 ,  G01N33/57407 ,  G01N33/57446 ,  G01N33/57492 ,  G01N2333/71 ,  G01N2800/52

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

公开(公告)号：EP2870477B1

公开(公告)日：2017-12-27

申请号：EP13765281.4

申请日：2013-07-09

Applicant: ScheBo Biotech AG

Inventor： SCHEEFERS, Hans ,  SCHEEFERS-BORCHEL, Ursula

IPC: G01N33/558 ,  G01N33/573 ,  G01N33/574 ,  G01N33/72

CPC classification number: G01N33/57419 ,  G01N33/558 ,  G01N33/573 ,  G01N33/57446 ,  G01N33/726 ,  G01N2333/91215

公开(公告)号：EP2844131B1

公开(公告)日：2017-10-11

申请号：EP13784595.4

申请日：2013-05-02

Applicant: Medial Research Ltd.

Inventor： KALKSTEIN, Nir ,  KINAR, Yaron ,  SHALEV, Varda ,  CHODICK, Gabriel ,  GOLDSHTEIN, Inbal

IPC: A61B5/00 ,  G06F19/00 ,  G01N33/574

CPC classification number: G06F19/345 ,  A61B5/7275 ,  G01N33/57419 ,  G01N33/57446 ,  G01N2800/50 ,  G06F19/00 ,  G06N3/02 ,  G16H50/20 ,  G16H50/30

Abstract: A method of evaluating gastrointestinal cancer risk. The method comprises generating a set of features comprising a plurality of current blood test results from a blood collected from a target individual, providing at least one classifier generated according to an analysis of a plurality of respective historical blood test results of each of another of a plurality of sampled individuals, and evaluating, using a processor, a gastrointestinal cancer risk of the target individual by classifying the set of features using the at least one classifier.

公开(公告)号：EP3223016A1

公开(公告)日：2017-09-27

申请号：EP15860565.9

申请日：2015-07-29

Applicant: University Of Ulsan Foundation For Industry Cooperation

Inventor： CHOI, Eun Kyung ,  JEONG, Seong-Yun ,  SONG, Si Yeol ,  LEE, Kyoung Jin ,  SHIN, Seol Hwa ,  JU, Eun Jin

IPC: G01N33/574 ,  G01N33/58 ,  A61K47/50

CPC classification number: G01N33/574 ,  A61K47/00 ,  A61K49/00 ,  A61K49/0008 ,  C07K7/08 ,  G01N33/00 ,  G01N33/57446 ,  G01N33/58

Abstract: The present invention relates to a peptide for targeting gastric cancer, a composition for diagnosing radioresponsiveness-dependent gastric cancer using the peptide, and a drug delivery use of the peptide. A functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients. After establishing animal models similar to cancer microenvironments of actual patients and dividing them into an irradiated population and a non-irradiated population as a control group, targeting efficiency has been tested for respective peptides selected by screening peptides specifically binding to the respective populations. As such, the present invention can be finally utilized in the technical development of image diagnosis for predicting responsiveness to radiotherapy, and accordingly, in the development of customized targeted therapeutic agents.

Abstract translation: 本发明涉及用于靶向胃癌的肽，使用该肽诊断放射应答性依赖性胃癌的组合物，以及该肽的药物递送用途。 已经发现了一种能够靶向癌症的功能性肽，从而对患有癌症的个体患者实施个性化诊断和治疗，考虑到由于个体的遗传差异导致的不同治疗反应而导致各个患者的治疗情况不同的治疗期间出现的问题 耐心。 在建立与实际患者的癌症微环境相似的动物模型并将其分为照射群体和未照射群体作为对照组之后，针对通过筛选特异性结合各个群体的肽选择的各个肽测试了靶向效率。 这样，本发明最终可用于图像诊断的技术开发中，用于预测对放射疗法的响应性，并因此用于开发定制的靶向治疗剂。

公开(公告)号：EP3168233A3

公开(公告)日：2017-07-26

申请号：EP16204647.8

申请日：2014-05-15

Applicant: Kyoto University

Inventor： TAKETO, Makoto ,  SONOSHITA, Masahiro ,  SAKAI, Yoshiharu ,  KAWADA, Kenji ,  ITATANI, Yoshiro

IPC: C07K16/18 ,  A61K31/506 ,  C07K16/40 ,  C07K16/30

CPC classification number: G01N33/57496 ,  A61K31/506 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3046 ,  C07K16/40 ,  C07K2317/34 ,  G01N33/57446 ,  G01N2333/91205 ,  G01N2440/14

Abstract: The present invention relates to a method for determining prognosis of cancer in a subject, which comprises the step of detecting phosphorylation of a tyrosine residue at position 2681 of TRIO in a sample obtained from the subject.

公开(公告)号：EP2997378A4

公开(公告)日：2017-03-15

申请号：EP14798641

申请日：2014-05-15

Applicant: UNIV KYOTO

Inventor： TAKETO MAKOTO ,  SONOSHITA MASAHIRO ,  SAKAI YOSHIHARU ,  KAWADA KENJI ,  ITATANI YOSHIRO

IPC: G01N33/574 ,  C07K16/18

CPC classification number: G01N33/57496 ,  A61K31/506 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3046 ,  C07K16/40 ,  C07K2317/34 ,  G01N33/57446 ,  G01N2333/91205 ,  G01N2440/14

Abstract: The present invention relates to a method for determining prognosis of cancer in a subject, which comprises the step of detecting phosphorylation of a tyrosine residue at position 2681 of TRIO in a sample obtained from the subject.

Abstract translation: 本发明涉及一种用于确定受试者的癌症预后的方法，其包括在从受试者获得的样品中检测TRIO的2681位酪氨酸残基的磷酸化步骤。

公开(公告)号：EP2619585B1

公开(公告)日：2017-03-01

申请号：EP11758209.8

申请日：2011-09-21

Applicant: Immatics Biotechnologies GmbH

Inventor： SINGH, Harpreet ,  WALTER, Steffen ,  MENDRZYK, Regina ,  BRONTE, Vincenzo ,  MANDRUZZATO, Susanna

IPC: G01N33/574

CPC classification number: G01N33/57419 ,  G01N33/5047 ,  G01N33/5743 ,  G01N33/57438 ,  G01N33/57446

Abstract: The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.

公开(公告)号：EP3042203A2

公开(公告)日：2016-07-13

申请号：EP14781819.9

申请日：2014-09-08

Applicant: Leibniz - Institut für Analytische Wissenschaften - ISAS - e.V.

Inventor： SITEK, Barbara ,  MEYER, Helmut E. ,  MEGGER, Dominik A. ,  BRACHT, Thilo ,  PADDEN, Juliet ,  BABA, Hideo Andreas ,  SCHLAAK, Jörg Friedrich ,  WEBER, Fränk

IPC: G01N33/574

CPC classification number: G01N33/57446 ,  G01N33/57438 ,  G01N33/6848 ,  G01N2500/04 ,  G01N2560/00 ,  G01N2570/00 ,  G01N2800/52

Abstract: The invention relates to a method for identifying specific marker proteins (biomarkers) for cholangiocellular Carcinoma (CCC), the biomarkers for CCC identified by the method and the use thereof, in particular for diagnosis, surveillance and treatment. The invention further relates to a diagnostic device comprising the biomarkers for CCC and a Screening assay wherein these biomarkers for CCC are used to indentify novel pharmaceutical Compounds for treatment of CCC.

Abstract translation: 本发明涉及用于鉴定胆管细胞癌（CCC）的特异性标志物蛋白（生物标志物），通过该方法鉴定的CCC生物标志物及其用途，特别是用于诊断，监测和治疗的方法。 本发明进一步涉及包括用于CCC的生物标志物和筛选试验的诊断装置，其中用于CCC的这些生物标志物用于鉴定用于治疗CCC的新型药物化合物。

公开(公告)号：EP2886556A4

公开(公告)日：2016-03-23

申请号：EP13824875

申请日：2013-08-05

Applicant: KOREA RES INST OF BIOSCIENCE ,  SNU R&DB FOUNDATION

Inventor： KIM SE MI ,  KIM SANG JICK ,  MIN HYE JIN ,  SONG JIN MYEONG ,  LEE JUNG WEON ,  KIM HYE JIN ,  AHN HYE MI ,  CHOI IN PYO ,  RYU JI HYE

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2863 ,  C07K16/28 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/57419 ,  G01N33/57438 ,  G01N33/57446 ,  G01N33/577 ,  G01N2333/4703

Abstract: The present invention relates to a novel monoclonal antibody which is specifically bound to a transmembrane 4 L six family member 5 (TM4SF5) protein. More particularly, the present invention relates to a monoclonal antibody which is specifically bound to a human TM4SF5 protein, to polynucleotides coding for the monoclonal antibody, to an expression vector comprising the nucleotides, to a transformant with the vector introduced thereto, to a method for preparing the monoclonal antibody, to a composition comprising the monoclonal antibody, to a method for treating cancer using the monoclonal antibody, to a method for inhibiting liver metastasis of cancer, to a method for diagnosing cancer using the monoclonal antibody and to a cancer diagnosis kit comprising the monoclonal antibody.